Need professional-grade analysis? Visit stockanalysis.com
$205.26M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Atrium Therapeutics, Inc. (RNA) Price Performance
Atrium Therapeutics, Inc. (RNA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $13.53, down 6.11% from the previous close.
Over the past year, RNA has traded between a low of $12.32 and a high of $72.93. The stock has lost 55.9% over this period. It is currently 81.4% below its 52-week high.
Atrium Therapeutics, Inc. has a market capitalization of $205.26M.
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Compare Atrium Therapeutics, Inc.
Side-by-side comparison against top Healthcare peers.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $18.62M
- EBITDA
- $-49,308,000
- Profit Margin
- -265.88%
- EPS (TTM)
- -4.48
- Book Value
- -4.04
Technical Indicators
- 52 Week High
- $73.06
- 52 Week Low
- $12.29
- 50 Day MA
- $41.03
- 200 Day MA
- $50.32
- Beta
- N/A
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -3.28
- Price/Sales
- 11.03
- Price/Book
- -3.27
- Enterprise Value
- $205.26M